Pursuant to Regulation 30 and Regulation 33 of the SEBI (LODR)Regulations, 2015; the Board of Directors, at its meeting held today i.e. on February 12, 2026, through video conferencing ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Globalspace Technologies approved unaudited financial results for the quarter and nine months ended December 31, 2025, on both standalone and consolidated basis. Standalone Q3 revenue jumped to Rs 1,256.85 lakhs from Rs 907.51 lakhs a year ago (~38% YoY growth), while consolidated Q3 revenue rose to Rs 1,663.50 lakhs from Rs 1,268.98 lakhs (~31% YoY growth). Standalone Q3 PAT stood at Rs 46.27 lakhs (vs Rs 61.90 lakhs YoY), and consolidated Q3 PAT at Rs 36.22 lakhs (vs Rs 67.38 lakhs YoY). For 9M FY26, the company swung back to profit (standalone Rs 76.18 lakhs, consolidated Rs 40.18 lakhs) compared to losses in the prior-year period, which had a Rs 275.65 lakh exceptional charge. The company also disclosed a Rs 98 lakh corporate guarantee given to Axis Bank for an overdraft facility to its subsidiary Innopharm Healthcare Pvt Ltd. The auditor (Bansilal Shah & Co.) issued an unqualified review opinion but flagged that the inventory register was not updated and that there were delays in statutory payments during the quarter.
Strong top-line growth in Q3 is a positive signal, though the YoY dip in Q3 PAT shows margin pressure persists. The corporate guarantee to its subsidiary adds a modest contingent liability but is small relative to the company's equity base (~Rs 55 crore). Shareholders should note the auditor's observations on weak inventory controls and delayed statutory payments, which signal governance/compliance gaps.